Growth Metrics

Novavax (NVAX) Current Leases (2020 - 2025)

Historic Current Leases for Novavax (NVAX) over the last 9 years, with Q3 2025 value amounting to $5.0 million.

  • Novavax's Current Leases fell 4794.83% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 4794.83%. This contributed to the annual value of $7.0 million for FY2024, which is 7507.38% down from last year.
  • As of Q3 2025, Novavax's Current Leases stood at $5.0 million, which was down 4794.83% from $5.6 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Current Leases ranged from a high of $161.5 million in Q4 2021 and a low of $953000.0 during Q2 2023
  • Moreover, its 5-year median value for Current Leases was $9.7 million (2024), whereas its average is $49.1 million.
  • Per our database at Business Quant, Novavax's Current Leases crashed by 9923.31% in 2023 and then soared by 88919.2% in 2024.
  • Quarter analysis of 5 years shows Novavax's Current Leases stood at $161.5 million in 2021, then tumbled by 72.72% to $44.1 million in 2022, then crashed by 36.18% to $28.1 million in 2023, then tumbled by 75.07% to $7.0 million in 2024, then dropped by 28.15% to $5.0 million in 2025.
  • Its last three reported values are $5.0 million in Q3 2025, $5.6 million for Q2 2025, and $5.5 million during Q1 2025.